Chardan Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Chardan's estimated annual revenue is currently $35M per year.(i)
  • Chardan's estimated revenue per employee is $416,667

Employee Data

  • Chardan has 84 Employees.(i)
  • Chardan grew their employee count by -14% last year.

Chardan's People

NameTitleEmail/Phone
1
Co-Founder and Non-Executive ChairmanReveal Email/Phone
2
CEOReveal Email/Phone
3
CFOReveal Email/Phone
4
Managing Director, Chief Compliance OfficerReveal Email/Phone
5
VP Corporate AccessReveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
Director Human ResourcesReveal Email/Phone
8
Managing Director, Principal Investments & Co-Head, FinTech Investment BankingReveal Email/Phone
9
Chief Legal Officer/Managing DirectorReveal Email/Phone
10
Director Investment BankingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$75M2750%N/AN/A
#2
$35M74-7%N/AN/A
#3
$75M4183%N/AN/A
#4
$7.5M7-22%N/AN/A
#5
N/A20-9%N/AN/A
#6
$9070M5864N/AN/AN/A
#7
$7.5M5522%N/AN/A
#8
$15M154N/AN/AN/A
#9
$35M644-21%N/AN/A
#10
$35M48-8%N/AN/A
Add Company

What Is Chardan?

At Chardan Capital we are driven by the desire to deliver excellence to our clientsand a genuine passion for what we do. We pride ourselves on our ability to provide an unmatched level of high-touch, customized service. Chardan is known across the industry for our innovative thinking, enthusiasm, and dedication. We've developed a culture of integrity and transparency that, even as we grow rapidly, continues to be guided by a strong conscience and solid ethical values. Our experienced professionals pursue a deep understanding of our clients needs and leverage their global relationships to provide exceptional value and insight. With an established record of successover $12.9 billion raised through more than 250 transactionswe have earned a reputation as the firm companies depend on to close particularly complex and challenging deals. Our clients know that every investment opportunity we recommend is backed by years of market experience, that the research we deliver is detailed, objective, and tailored to their needs, and that every trade they place through us will be executed with precision and discretion. Clients look to Chardan for honest advice and high quality, creative investment ideasthey continue to work with us because we consistently deliver on that promise. Disclaimer: Information posted on this Web site is believed to be reliable at the time of posting; Chardan Capital Markets, LLC and its affiliates cannot, however, guarantee the accuracy or completeness of such information or make any warranties with regard to the results to be obtained from its use. Information on this Web site is not intended to provide financial, legal, accounting or tax advice and should not be relied upon in that regard. Chardan Capital Markets, LLC and its affiliates are not responsible in any manner for direct, indirect, special or consequential damages howsoever caused, arising out of the use of this Web site or any of its content.

keywords:N/A

N/A

Total Funding

84

Number of Employees

$35M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Chardan News

2022-04-20 - Transcript : Iovance Biotherapeutics, Inc. Presents at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Conference, Apr-26-2022 01:30 PM

... Inc. Presents at Chardan's 6th Annual Genetic Medicines and Cell Therapy Conference, Apr-26-2022 01:30 PM. 04/26/2022 | 01:30pm EDT. share with twitter.

2022-04-19 - Iovance Biotherapeutics to Present at Chardan Genetic ...

Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing ... Iovance Biotherapeutics, Inc. - (GLOBE...

2022-04-17 - Chardan Acts as M&A and Lead Financial Advisor in Neos ...

NEW YORK, April 20, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced its role as lead financial advisor in the sale of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21M8422%N/A
#2
$12.2M848%N/A
#3
$12.6M841%N/A
#4
$11.8M842%$142.6M
#5
$10.9M840%$10.5M